NOTCH3 and B-cell chronic lymphocytic leukemia: On the other hand, the combination of Notch inhibitors such as GSI and monoclonal antibodies, except anti-Notch3 and anti-DLL1, with alkylating drugs such as cyclophosphamide and bendamustine, counteracted stroma-dependent resistance of CLL cells to these drugs and reverted the above-mentioned molecular changes without affecting the viability of stromal cells [381].